Registered forecast

85% registered probability event by 2027-02-07 Unresolved

FDA approves Verastem’s NDA for the AVMAPKI FAKZYNJA CO-PACK Blister Pack (avutometinib tablets; defactinib tablets) on or before the disclosed PDUFA goal date of 2027-02-07

FF-066 Registered Unresolved
registered due
Our estimate
85%
an estimate, not a reading
Action by
2027-02-07
known at this date
Reading window
2026-11-11 → 2027-02-07
known at this date
Decision stage
  1. 5 Guideline
  2. 6 Regulatory
  3. 7 Coverage
Baselines it has to beat
  • Authority base rate 85%
  • Calendar cycle 80%
  • Analyst proxy 85%
  • Known at this date
  • The registered estimate, uncertain
  • Not yet knowable at this date

At this date the record was registered at 85% and the deadline had not been reached. The outcome was not yet knowable.

The outcome is not yet knowable at this date.

nextconsensus.com/forecast/ff-066/ registry snapshot 2026-11-21 Share image

NextConsensus registered this probability on 2026-11-10. It is one of 36 registered FDA goal-date forecasts.

The proposition

What was registered

The FDA takes an approval action on Verastem, Inc.’s New Drug Application for the AVMAPKI FAKZYNJA CO-PACK Blister Pack, the co-packaged presentation of avutometinib tablets and defactinib tablets, with an approval action date on or before 2027-02-07, the PDUFA date disclosed in Verastem’s Q3 2026 results release and presentation filed 2026-11-05.
Who decides
US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) (US)
Who has to act
Rung 6: Regulatory action — Label/indication change, approval action, REMS modification, or withdrawal by FDA, EMA, PMDA, Health Canada, etc.
Counted with
FDA action by goal date
Scope
Co-packaged tablet presentation of the regimen approved for KRAS-mutated recurrent low-grade serous ovarian cancer

The estimate

Our estimate and what it has to beat

85% our estimate, method v0.1.0 · frozen at the 2026-11-10 cutoff

The estimate that the named body takes the action by the deadline, from what was public at the cutoff.

The alternatives it was registered against, each with the reasoning that produced it. They were set at registration: how often this kind of decision happens on time, what the calendar alone suggests, and a reading of the same public record without this method. Each one's reasoning shows whether it is a count of past decisions or an estimate.

Authority base rate 85%

ESTIMATE FROM THE SHAPE OF THE CLASS, NOT AN ENUMERATED COUNT. Applications for a new dosage form of a drug the same sponsor already markets, at the approved dose, are approved at their first goal date in a large majority of cases; the complete responses that do occur are mostly on manufacturing or bioequivalence. The calendar's own met-goal-date share for disclosed PDUFA dates does not exist yet.

Calendar cycle 80%

A clock-only model: the goal date is inside the window, FDA meets most goal dates, and most first-cycle actions on applications under Priority Review are approvals. With no evidence input it cannot tell a formulation change from a new molecule.

Analyst proxy 85%

An analyst reading the same filings on 2026-11-10 would weigh a formulation and packaging change at the approved dose, Priority Review and a sponsor with an approved product, against new-tablet manufacturing risk and a small sponsor. Estimated by reconstructing that read, not by surveying analysts.

Regulatory action (FDA): offered on judgment, with no calibration figure until 15 in the class have resolved.

The method and every record are public, so you can check the work.

The clock

Dates that constrain the record

Evidence as of
2026-11-10
Nothing after this date informed the estimate. known at this date
Registered
2026-11-10
Frozen and hashed. known at this date
Reading window
2026-11-11 → 2027-02-07
When the outcome can be read against the rule. known at this date
Event by
2027-02-07
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar known at this date
ledger 7a529f4585bb6406a54128ef8e7cfe782f889f95fbaa191a828c0a4e5d0ba3c5
· operator record jc-1794354011667-afda478c

Around this record

Confidential Asset & Milestone Evaluation

Evaluating an asset or milestone that the FDA could move?

Name the asset, the deciding authority, and the date your team prepares for: a P&T review, an HTA submission, a label negotiation, a deal closing, or a milestone dispute. It can be an asset you sponsor, evaluate, finance, advise on, or rely on. Every commercial evaluation applies the same pre-registration standard and primary-source verification as this record, delivered privately under mutual NDA.

$9,500 · 10 business days One milestone, authority, and target date: the dated evidence baseline, authority divergence redline, evidence stall assessment, and transition probability. Delivered within ten business days of the kickoff call, or you don't pay.
Under mutual NDA Held to the same standard as this public record: who decides, the resolution rule, and the baselines.
Reconstructing a record? For an earnout, milestone dispute, or expert report: the $5,000 Historical Evidence-State Dossier, one proposition at one cutoff, 5 business days, no probabilities. For an asset's whole history across the class: the $35,000 Regulatory & Coverage Diligence Dossier, 15 business days.

Resolution

How we’ll check the result

The application number of the Blister Pack NDA was not public at the cutoff, and openFDA listed only NDA219616, the marketed CO-PACK of avutometinib capsules and defactinib tablets, for the applicant and for either ingredient (SRC-005, SRC-006, SRC-007). The adjudicator identifies the qualifying approval by its content, never by a name the adjudicator infers: an approval action that approves avutometinib in a tablet dosage form, co-packaged with defactinib tablets, under any applicant (Verastem, Inc. or a Verastem subsidiary or licensee) and any proprietary name. It may appear as the ORIG submission of a new application or as a supplement to NDA219616; either counts. The capsule presentation approved in 2025 does not count. Resolves YES if the openFDA Drugs@FDA records returned by https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22AVUTOMETINIB%22&limit=100 and by https://api.fda.gov/drug/drugsfda.json?search=sponsor_name:%22VERASTEM+INC%22&limit=100, read together, contain such an approval: a submission with submission_status AP and a submission_status_date on or before 2027-02-07, confirmed as the tablet presentation by its product listing, approval letter or label. An approval for a narrower population or fewer dose packs than the applicant sought still resolves YES. A tentative approval does not count. Resolves NO if no approval action is dated on or before 2027-02-07: a complete response letter, a goal-date extension, withdrawal or no action. The goal date is frozen as disclosed at the cutoff; a later extension does not move it, and an approval dated after 2027-02-07 resolves NO as occurred_after_deadline. 2027-02-07 is a Sunday; an approval action dated on the preceding Friday or earlier counts. Read no earlier than 2027-02-21. If openFDA has not refreshed by then, or both queries return no qualifying record, the Drugs@FDA web record (https://www.accessdata.fda.gov/scripts/cder/daf/, searched by the names avutometinib, defactinib and AVMAPKI) governs, under the same identification test. Resolves unresolvable only if none of these sources can be read after the read floor. Resolves VOID, with the reason recorded, only if FDA withdraws every public record of approval actions named above without an equivalent public successor, so that no approval date for this product can be read; while any of them publishes it, the rule stands.

Source the rule names: https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22AVUTOMETINIB%22&limit=100, https://api.fda.gov/drug/drugsfda.json?search=sponsor_name:%22VERASTEM+INC%22&limit=100, https://www.accessdata.fda.gov/scripts/cder/daf/

After the deadline, the founder (Kanav Jain) reads the outcome against the frozen public source; unratified automated readings are labelled machine-resolved and excluded from class calibration figures.

What this record will show once it resolves

Beside every result, the count for its class (FDA action by goal date): registered, resolved, unresolved, and expired. One forecast is one instance, not a rate.

The finding
As the rule above reads it: occurred on time, did not occur, or left unscored.
The readers and their sources
After the deadline, the founder (Kanav Jain) reads the frozen public source named above under the registered rule (or automated checks record a machine-resolved reading). Who adjudicated it and the source read are published here so any reader can verify the outcome. Adjudication applies the frozen rule to the named public source so any reader can verify the reading independently.
The number against its baselines
85% beside three baselines, each scored by the same rule (squared error), so a reader can see how the record did against each of them.

Email me when FF-066 resolves

One email when the result is published, then nothing; the address is deleted a month later.

Reasoning

What the number rests on

The facts it was built from are below, as they stood at the cutoff, with every source archived; each baseline above carries the reasoning that produced it. The written mechanism and the conditions that would make the proposition ill-posed were frozen with the record, are held in the ledger, and are covered by its hash.

The state of the record at the cutoff

Recorded as they stood on 2026-11-10.

review pathway
Priority Review, granted at acceptance on 2026-10-07 (SRC-001, SRC-002). Center CDER is the drafter's understanding (a small-molecule NDA), unverified.
submission type
New Drug Application for a new dosage form and presentation (avutometinib 3.2 mg tablet co-packaged with defactinib 200 mg tablets) of the combination approved as NDA219616; application number not public (SRC-001, SRC-003, SRC-005).
evidence class
Formulation and presentation change at the approved dose and regimen; no new efficacy trial is named in the archived sources (SRC-003). Original approval rested on the single-arm phase 2 RAMP 201 study (SRC-003).
pivotal n
not applicable — no new efficacy study is named; the submission's bridging data are not described in the archived sources
endpoint type
not applicable — the application concerns formulation and packaging, not a new efficacy endpoint
approved competitors in class
none for this presentation; the capsule CO-PACK (NDA219616) is the sponsor's own approved product for KRAS-mutated recurrent LGSOC after prior systemic therapy (SRC-004, SRC-005)
months since last guideline revision
not applicable — no guideline is the subject of this proposition
panel cycle position
not applicable — the act is an FDA approval action
sponsor request status
NDA accepted 2026-10-07 with Priority Review; announced 2026-10-14; PDUFA date February 7, 2027 disclosed 2026-11-05 (SRC-001, SRC-002, SRC-003).
odac referral
none announced in the archived sources
sponsor state change
A chief executive transition effective 2027-01-01 and the termination of an at-the-market prospectus, both announced 2026-10-14 (SRC-001); neither is recorded as bearing on the application.

Sources

Everything the estimate was built from

Each was retrieved on or before the 2026-11-10 cutoff and archived at the digest shown. If a publisher edits a page after the fact, the digest stops matching and the substitution is visible.

  1. SRC-001 Verastem Form 8-K filed 2026-10-14. Item 8.01: on 2026-10-07 FDA accepted for review the company's Blister Pack New Drug Application, with action in the first quarter of 2027, and granted it Priority Review. Item 5.02: chief executive transition effective 2027-01-01; Item 8.01 also records termination of the at-the-market prospectus.

    https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_8k.htm

    Retrieved 2026-11-10 · sha256 54ce2c03f2b2a508c9a57928739e240b0d13b5064fb6669ca461f04a5ce398bf

  2. SRC-002 Exhibit 99.1 to Verastem's Form 10-Q filed 2026-11-05: Q3 2026 results release. FDA accepted the NDA for the AVMAPKI FAKZYNJA CO-PACK Blister Pack with Priority Review and an FDA decision by February 7, 2027; the current CO-PACK (avutometinib capsules; defactinib tablets) generated USD 24.0 million net product revenue in Q3 2026.

    https://www.sec.gov/Archives/edgar/data/1526119/000110465926123305/vstm-ex99d1.htm

    Retrieved 2026-11-10 · sha256 2dfe670b3cdc5dd9ba24c017fc2796ead5bd5a5da770d2f016361ee0ed88aa05

  3. SRC-003 Exhibit 99.1 to Verastem's Form 8-K filed 2026-11-05: Q3 2026 corporate presentation. Slide 'AVMAPKI FAKZYNJA CO-PACK Blister Pack': FDA Priority Review granted, PDUFA date February 7, 2027; the proposed pack replaces four refrigerated 0.8 mg avutometinib capsules per dose with one 3.2 mg avutometinib tablet, with defactinib 200 mg tablets, standard and reduced dose packs and no refrigeration; 'Proposed formulation and packaging changes are subject to FDA approval.' RAMP 301 confirmatory trial design (avutometinib 3.2 mg twice weekly with defactinib 200 mg twice daily).

    https://www.sec.gov/Archives/edgar/data/1526119/000110465926123386/tm2628982d2_ex99-1.htm

    Retrieved 2026-11-10 · sha256 eeebefe9a8efa3b7a985077fa908b28944541160000c7a7489e2fe7ef72a2815

  4. SRC-004 Verastem Form 10-Q for the quarter ended 2026-09-30, filed 2026-11-05: the marketed CO-PACK is approved by FDA for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy; in October 2026 FDA accepted the NDA for the Blister Pack with Priority Review and a decision expected by February 7, 2027; RAMP 301 topline expected mid-2027.

    https://www.sec.gov/Archives/edgar/data/1526119/000110465926123305/vstm-20260930x10q.htm

    Retrieved 2026-11-10 · sha256 194e132f933ff0be73cbac32fba36eb21fb18b82e89e113e969fb675c475b180

  5. SRC-005 openFDA drugsfda products.active_ingredients.name:"AVUTOMETINIB", retrieved 2026-11-10: one application, NDA219616 (Verastem), AVMAPKI FAKZYNJA CO-PACK, capsule and tablet (avutometinib potassium eq 0.8 mg base; defactinib hydrochloride eq 200 mg base); ORIG 1 approved 2025-05-08; no supplement listed and no avutometinib tablet product.

    https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22AVUTOMETINIB%22&limit=100

    Retrieved 2026-11-10 · sha256 e9446b89f871ee609dcb87a63daefbf47941b15dba008f86f263602b268dd58e

  6. SRC-006 openFDA drugsfda sponsor_name:"VERASTEM INC", retrieved 2026-11-10: one application, NDA219616; no other Verastem application.

    https://api.fda.gov/drug/drugsfda.json?search=sponsor_name:%22VERASTEM+INC%22&limit=100

    Retrieved 2026-11-10 · sha256 e9446b89f871ee609dcb87a63daefbf47941b15dba008f86f263602b268dd58e

  7. SRC-007 openFDA drugsfda products.active_ingredients.name:"DEFACTINIB", retrieved 2026-11-10: one application, NDA219616; no other defactinib application.

    https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22DEFACTINIB%22&limit=100

    Retrieved 2026-11-10 · sha256 e9446b89f871ee609dcb87a63daefbf47941b15dba008f86f263602b268dd58e